

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

BIODELIVERY SCIENCES INTERNATIONAL INC  
Form SC 13G  
January 08, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d - 102)

Under the Securities Exchange Act of 1934

BIODELIVERY SCIENCES INTERNATIONAL, INC.

-----  
(Name of Issuer)

Common Stock, par value \$0.001 per share

-----  
(Title of Class of Securities)

09060J106

-----  
(CUSIP Number)

December 29, 2006

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-----  
CUSIP No. 47008R103

-----  
1 NAME OF REPORTING PERSON: Laurus Master Fund, Ltd.  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 98-0337673

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

(a)   
 (b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

5 SOLE VOTING POWER

0 shares of Common Stock.\*

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6 SHARED VOTING POWER

1,392,420 shares of Common Stock.\*

7 SOLE DISPOSITIVE POWER

0 shares of Common Stock.\*

8 SHARED DISPOSITIVE POWER

1,392,420 shares of Common Stock.\*

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,392,420 shares of Common Stock.

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.99%\*

12 TYPE OF REPORTING PERSON

CO

\* Based on 13,938,146 shares of the common stock, par value \$0.001 per share (the "Shares") of BioDelivery Sciences International, Inc., a Delaware corporation (the "Company") outstanding, as represented in the Company's Quarterly Report on Form 10-QSB for the period ended September 30, 2006. As of December 29, 2006, Laurus Master Fund, Ltd. (the "Fund") held (i) a common stock purchase warrant (the "January Warrant #1") to acquire 22,500 Shares at an exercise price of \$0.01 per share, subject to certain adjustments, (ii) a common stock purchase warrant (the "January Warrant #2") to acquire 39,574 Shares at an exercise price of \$.01, subject to certain adjustments, (iii) a common stock purchase warrant (the "January Warrant #3") to acquire 29,700 Shares at an exercise price of \$.01, subject to certain adjustments; (iv) a common stock purchase warrant (the "January Warrant #4") to acquire 350,000 Shares at an exercise price of \$3.00, subject to certain adjustments, (v) a common stock purchase warrant (the "January Warrant #5") to acquire 483,871 Shares at an exercise price of \$3.88, subject to certain adjustments, (vi) a common stock purchase warrant (the "July Warrant #1") to acquire 47,113 Shares at an exercise

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

price of \$3.00, subject to certain adjustments; (vii) a common stock purchase warrant (the "July Warrant #2" and together with the January Warrant #1, the January Warrant #2, the January Warrant #3, the January Warrant #4, the January Warrant #5 and the July Warrant #1, the "Early Warrants") to acquire 110,000 Shares, at an exercise price of \$3.88, subject to certain adjustments, (viii) a common stock purchase Warrant (the "December Warrant #1") to acquire 943,305 Shares, at an exercise price of \$3.05, subject to certain adjustments, (vii) a common stock purchase warrant (the "December Warrant #2" and together with the December Warrant #1, the "December Warrants") to acquire 556,695 Shares, at an exercise price of \$3.05 per share, subject to certain adjustments, (viii) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #1"); (ix) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #2", and together with Note #1, the "Notes"); and (x) 19,403 Shares. The Early Warrants and the Notes contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 4.99% of the Shares then issued and outstanding (the "4.99% Issuance Limitation"). The December Warrants contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 9.99% of the Shares then issued and outstanding (the "9.99% Issuance Limitation" and together with the 4.99% Issuance Limitation, the "Issuance Limitations"). The Issuance Limitations may be waived by the Fund upon 75 days prior notice to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and/or continuance of an Event of Default (as defined in and pursuant to the terms of the applicable instrument). The Fund is managed by Laurus Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and share sole voting and investment power over the securities owned by the Fund reported in this Schedule 13G, as amended.

-----  
 CUSIP No. 47008R103  
 -----

1 NAME OF REPORTING PERSON: Laurus Capital Management, LLC  
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 13-4150669  
 -----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
 (a)   
 (b)   
 -----

3 SEC USE ONLY  
 -----

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware  
 -----

5 SOLE VOTING POWER  
 0 shares of Common Stock.\*  
 -----

NUMBER OF 6 SHARED VOTING POWER  
 SHARES  
 BENEFICIALLY 1,392,420 shares of Common Stock.\*  
 OWNED BY  
 -----

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

EACH 7 SOLE DISPOSITIVE POWER  
 REPORTING PERSON 0 shares of Common Stock.\*  
 WITH -----  
 8 SHARED DISPOSITIVE POWER  
 1,392,420 shares of Common Stock.\*

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
 1,392,420 shares of Common Stock.

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
 9.99%

12 TYPE OF REPORTING PERSON  
 OO

\* Based on 13,938,146 shares of the common stock, par value \$0.001 per share (the "Shares") of BioDelivery Sciences International, Inc., a Delaware corporation (the "Company") outstanding, as represented in the Company's Quarterly Report on Form 10-QSB for the period ended September 30, 2006. As of December 29, 2006, Laurus Master Fund, Ltd. (the "Fund") held (i) a common stock purchase warrant (the "January Warrant #1") to acquire 22,500 Shares at an exercise price of \$0.01 per share, subject to certain adjustments, (ii) a common stock purchase warrant (the "January Warrant #2") to acquire 39,574 Shares at an exercise price of \$.01, subject to certain adjustments, (iii) a common stock purchase warrant (the "January Warrant #3") to acquire 29,700 Shares at an exercise price of \$.01, subject to certain adjustments; (iv) a common stock purchase warrant (the "January Warrant #4") to acquire 350,000 Shares at an exercise price of \$3.00, subject to certain adjustments, (v) a common stock purchase warrant (the "January Warrant #5") to acquire 483,871 Shares at an exercise price of \$3.88, subject to certain adjustments, (vi) a common stock purchase warrant (the "July Warrant #1") to acquire 47,113 Shares at an exercise price of \$3.00, subject to certain adjustments; (vii) a common stock purchase warrant (the "July Warrant #2" and together with the January Warrant #1, the January Warrant #2, the January Warrant #3, the January Warrant #4, the January Warrant #5 and the July Warrant #1, the "Early Warrants") to acquire 110,000 Shares, at an exercise price of \$3.88, subject to certain adjustments, (viii) a common stock purchase Warrant (the "December Warrant #1") to acquire 943,305 Shares, at an exercise price of \$3.05, subject to certain adjustments, (vii) a common stock purchase warrant (the "December Warrant #2" and together with the December Warrant #1, the "December Warrants") to acquire 556,695 Shares, at an exercise price of \$3.05 per share, subject to certain adjustments, (viii) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #1"); (ix) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #2", and together with Note #1, the "Notes"); and (x) 19,403 Shares. The Early Warrants and the Notes contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 4.99% of the Shares then issued and outstanding (the "4.99% Issuance Limitation"). The December Warrants contain

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 9.99% of the Shares then issued and outstanding (the "9.99% Issuance Limitation" and together with the 4.99% Issuance Limitation, the "Issuance Limitations"). The Issuance Limitations may be waived by the Fund upon 75 days prior notice to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and/or continuance of an Event of Default (as defined in and pursuant to the terms of the applicable instrument). The Fund is managed by Laurus Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and share sole voting and investment power over the securities owned by the Fund reported in this Schedule 13G, as amended.

-----  
CUSIP No. 47008R103  
-----

1 NAME OF REPORTING PERSON: David Grin  
-----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3 SEC USE ONLY  
-----

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Israel  
-----

5 SOLE VOTING POWER

0 shares of Common Stock.\*  
-----

NUMBER OF SHARES

BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6 SHARED VOTING POWER

1,392,420 shares of Common Stock.\*  
-----

7 SOLE DISPOSITIVE POWER

0 shares of Common Stock.\*  
-----

8 SHARED DISPOSITIVE POWER

1,392,420 shares of Common Stock.\*  
-----

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,392,420 shares of Common Stock.  
-----

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.99%  
-----

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

12 TYPE OF REPORTING PERSON

IN

-----

\* Based on 13,938,146 shares of the common stock, par value \$0.001 per share (the "Shares") of BioDelivery Sciences International, Inc., a Delaware corporation (the "Company") outstanding, as represented in the Company's Quarterly Report on Form 10-QSB for the period ended September 30, 2006. As of December 29, 2006, Laurus Master Fund, Ltd. (the "Fund") held (i) a common stock purchase warrant (the "January Warrant #1") to acquire 22,500 Shares at an exercise price of \$0.01 per share, subject to certain adjustments, (ii) a common stock purchase warrant (the "January Warrant #2") to acquire 39,574 Shares at an exercise price of \$.01, subject to certain adjustments, (iii) a common stock purchase warrant (the "January Warrant #3") to acquire 29,700 Shares at an exercise price of \$.01, subject to certain adjustments; (iv) a common stock purchase warrant (the "January Warrant #4") to acquire 350,000 Shares at an exercise price of \$3.00, subject to certain adjustments, (v) a common stock purchase warrant (the "January Warrant #5") to acquire 483,871 Shares at an exercise price of \$3.88, subject to certain adjustments, (vi) a common stock purchase warrant (the "July Warrant #1") to acquire 47,113 Shares at an exercise price of \$3.00, subject to certain adjustments; (vii) a common stock purchase warrant (the "July Warrant #2" and together with the January Warrant #1, the January Warrant #2, the January Warrant #3, the January Warrant #4, the January Warrant #5 and the July Warrant #1, the "Early Warrants") to acquire 110,000 Shares, at an exercise price of \$3.88, subject to certain adjustments, (viii) a common stock purchase Warrant (the "December Warrant #1") to acquire 943,305 Shares, at an exercise price of \$3.05, subject to certain adjustments, (vii) a common stock purchase warrant (the "December Warrant #2" and together with the December Warrant #1, the "December Warrants") to acquire 556,695 Shares, at an exercise price of \$3.05 per share, subject to certain adjustments, (viii) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #1"); (ix) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #2", and together with Note #1, the "Notes"); and (x) 19,403 Shares. The Early Warrants and the Notes contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 4.99% of the Shares then issued and outstanding (the "4.99% Issuance Limitation"). The December Warrants contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 9.99% of the Shares then issued and outstanding (the "9.99% Issuance Limitation" and together with the 4.99% Issuance Limitation, the "Issuance Limitations"). The Issuance Limitations may be waived by the Fund upon 75 days prior notice to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and/or continuance of an Event of Default (as defined in and pursuant to the terms of the applicable instrument). The Fund is managed by Laurus Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and share sole voting and investment power over the securities owned by the Fund reported in this Schedule 13G, as amended.

-----

CUSIP No. 47008R103

1 NAME OF REPORTING PERSON: Eugene Grin

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

-----  
 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
 (a)    
 (b)    
 -----

3 SEC USE ONLY  
 -----

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States  
 -----

	5	SOLE VOTING POWER	
			0 shares of Common Stock.*
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER	
			1,392,420 shares of Common Stock.*
	7	SOLE DISPOSITIVE POWER	
			0 shares of Common Stock.*
	8	SHARED DISPOSITIVE POWER	
			1,392,420 shares of Common Stock.*

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,392,420 shares of Common Stock.  
 -----

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

X

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.99%  
 -----

12 TYPE OF REPORTING PERSON

IN  
 -----

-----  
 \* Based on 13,938,146 shares of the common stock, par value \$0.001 per share (the "Shares") of BioDelivery Sciences International, Inc., a Delaware corporation (the "Company") outstanding, as represented in the Company's Quarterly Report on Form 10-QSB for the period ended September 30, 2006. As of December 29, 2006, Laurus Master Fund, Ltd. (the "Fund") held (i) a common stock purchase warrant (the "January Warrant #1") to acquire 22,500 Shares at an exercise price of \$0.01 per share, subject to certain adjustments, (ii) a common stock purchase warrant (the "January Warrant #2") to acquire 39,574 Shares at an exercise price of \$.01, subject to certain adjustments, (iii) a common stock purchase warrant (the "January Warrant #3") to acquire 29,700 Shares at an exercise price of \$.01, subject to certain adjustments; (iv) a common stock purchase warrant (the "January Warrant #4") to acquire 350,000 Shares at an exercise price of \$3.00, subject to certain adjustments, (v) a common stock purchase warrant (the "January Warrant #5") to acquire 483,871 Shares at an

## Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

exercise price of \$3.88, subject to certain adjustments, (vi) a common stock purchase warrant (the "July Warrant #1") to acquire 47,113 Shares at an exercise price of \$3.00, subject to certain adjustments; (vii) a common stock purchase warrant (the "July Warrant #2" and together with the January Warrant #1, the January Warrant #2, the January Warrant #3, the January Warrant #4, the January Warrant #5 and the July Warrant #1, the "Early Warrants") to acquire 110,000 Shares, at an exercise price of \$3.88, subject to certain adjustments, (viii) a common stock purchase Warrant (the "December Warrant #1") to acquire 943,305 Shares, at an exercise price of \$3.05, subject to certain adjustments, (vii) a common stock purchase warrant (the "December Warrant #2" and together with the December Warrant #1, the "December Warrants") to acquire 556,695 Shares, at an exercise price of \$3.05 per share, subject to certain adjustments, (viii) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #1"); (ix) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #2", and together with Note #1, the "Notes"); and (x) 19,403 Shares. The Early Warrants and the Notes contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 4.99% of the Shares then issued and outstanding (the "4.99% Issuance Limitation"). The December Warrants contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 9.99% of the Shares then issued and outstanding (the "9.99% Issuance Limitation" and together with the 4.99% Issuance Limitation, the "Issuance Limitations"). The Issuance Limitations may be waived by the Fund upon 75 days prior notice to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and/or continuance of an Event of Default (as defined in and pursuant to the terms of the applicable instrument). The Fund is managed by Laurus Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and share sole voting and investment power over the securities owned by the Fund reported in this Schedule 13G, as amended.

Item 1(a). Name of Issuer: BIODELIVERY SCIENCES INTERNATIONAL, INC.

Item 1(b). Address of Issuer's Principal Executive Offices:  
185 South Orange Avenue, Administrative Building 4, Newark,  
New Jersey 07103

Item 2(a). Name of Person Filing: Laurus Master Fund, Ltd.

This Schedule 13G, as amended, is also filed on behalf of Laurus Capital Management, LLC, a Delaware limited liability company, Eugene Grin and David Grin. Laurus Capital Management, LLC manages Laurus Master Fund, Ltd. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and share sole voting and investment power over the shares owned by Laurus Master Fund, Ltd. Information related to each of Laurus Capital Management, LLC, Eugene Grin and David Grin is set forth on Appendix A hereto.

Item 2(b). Address of Principal Business Office or if none, Residence:



## Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

c/o Laurus Capital Management, LLC, 825 Third Avenue, 14th Floor, New York, NY 10022

- Item 2(c).           Citizenship:   Cayman Islands
- Item 2(d).           Title of Class of Securities:   Common Stock
- Item 2(e).           CUSIP Number:   09060J106
- Item 3.             Not Applicable
- Item 4.             Ownership:
- (a)       Amount Beneficially Owned:  1,392,420 shares of Common Stock\*  
                  (b) Percent of Class:  9.99%\*
- (c)       Number of shares as to which such person has:
- (i)     sole power to vote or to direct the vote:  0 shares of  
                          Common Stock\*
- (ii)    shared power to vote or to direct the vote:  1,392,420  
                          shares of Common Stock\*
- (iii)   sole power to dispose or to direct the disposition of:  0  
                          shares of Common Stock\*
- (iv)    shared power to dispose or to direct the disposition of:  
                          1,392,420 shares of Common Stock\*
- Item 5.             Ownership of Five Percent or Less of a Class: Not applicable
- Item 6.             Ownership of More than Five Percent on Behalf of Another  
                  Person: Not applicable
- Item 7.             Identification and Classification of Subsidiary Which Acquired  
                  the Securities: Not applicable
- Item 8.             Identification and Classification of Members of the Group: Not  
                  applicable
- Item 9.             Notice of Dissolution of Group: Not applicable
- Item 10.            Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

-----  
\* Based on 13,938,146 shares of the common stock, par value \$0.001 per share (the "Shares") of BioDelivery Sciences International, Inc., a Delaware corporation (the "Company") outstanding, as represented in the Company's Quarterly Report on Form 10-QSB for the period ended September 30, 2006. As of December 29, 2006, Laurus Master Fund, Ltd. (the "Fund") held (i) a common stock purchase warrant (the "January Warrant #1") to acquire 22,500 Shares at an

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

exercise price of \$0.01 per share, subject to certain adjustments, (ii) a common stock purchase warrant (the "January Warrant #2") to acquire 39,574 Shares at an exercise price of \$.01, subject to certain adjustments, (iii) a common stock purchase warrant (the "January Warrant #3") to acquire 29,700 Shares at an exercise price of \$.01, subject to certain adjustments; (iv) a common stock purchase warrant (the "January Warrant #4") to acquire 350,000 Shares at an exercise price of \$3.00, subject to certain adjustments, (v) a common stock purchase warrant (the "January Warrant #5") to acquire 483,871 Shares at an exercise price of \$3.88, subject to certain adjustments, (vi) a common stock purchase warrant (the "July Warrant #1") to acquire 47,113 Shares at an exercise price of \$3.00, subject to certain adjustments; (vii) a common stock purchase warrant (the "July Warrant #2" and together with the January Warrant #1, the January Warrant #2, the January Warrant #3, the January Warrant #4, the January Warrant #5 and the July Warrant #1, the "Early Warrants") to acquire 110,000 Shares, at an exercise price of \$3.88, subject to certain adjustments, (viii) a common stock purchase Warrant (the "December Warrant #1") to acquire 943,305 Shares, at an exercise price of \$3.05, subject to certain adjustments, (vii) a common stock purchase warrant (the "December Warrant #2" and together with the December Warrant #1, the "December Warrants") to acquire 556,695 Shares, at an exercise price of \$3.05 per share, subject to certain adjustments, (viii) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #1"); (ix) a Convertible Term Note in the aggregate principal amount of \$2,500,000, a portion of which is convertible into Shares at a conversion rate of \$2.45, subject to certain adjustments ("Note #2", and together with Note #1, the "Notes"); and (x) 19,403 Shares. The Early Warrants and the Notes contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 4.99% of the Shares then issued and outstanding (the "4.99% Issuance Limitation"). The December Warrants contain an issuance limitation prohibiting the Fund from exercising those securities to the extent that such exercise would result in beneficial ownership by the Fund of more than 9.99% of the Shares then issued and outstanding (the "9.99% Issuance Limitation" and together with the 4.99% Issuance Limitation, the "Issuance Limitations"). The Issuance Limitations may be waived by the Fund upon 75 days prior notice to the Company and shall automatically become null and void following notice to the Issuer of the occurrence and/or continuance of an Event of Default (as defined in and pursuant to the terms of the applicable instrument). The Fund is managed by Laurus Capital Management, LLC. Eugene Grin and David Grin, through other entities, are the controlling principals of Laurus Capital Management, LLC and share sole voting and investment power over the securities owned by the Fund reported in this Schedule 13G, as amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 8, 2007

Date

//s// Eugene Grin

-----  
Eugene Grin

Director

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G

APPENDIX A

A. Name: Laurus Capital Management, LLC, a Delaware  
limited liability company  
Business Address: 825 Third Avenue, 14th Floor  
New York, New York 10022  
Place of Organization: Delaware

B. Name: Eugene Grin  
Business Address: 825 Third Avenue, 14th Floor  
New York, New York 10022  
Principal Occupation: Director of Laurus Master Fund, Ltd.  
Principal of Laurus Capital Management, LLC  
Citizenship: United States

C. Name: David Grin  
Business Address: 825 Third Avenue, 14th Floor  
New York, New York 10022  
Principal Occupation: Director of Laurus Master Fund, Ltd.  
Principal of Laurus Capital Management, LLC  
Citizenship: Israel

Each of Laurus Capital Management, LLC, Eugene Grin and David Grin hereby agrees, by their execution below, that the Schedule 13G, as amended, to which this Appendix A is attached is filed on behalf of each of them, respectively.

Laurus Capital Management, LLC

//s// Eugene Grin

-----  
Eugene Grin  
Principal  
December 29, 2006

//s// David Grin

-----  
David Grin, on his individual behalf  
December 29, 2006

//s// Eugene Grin

-----  
Eugene Grin, on his individual behalf  
December 29, 2006